Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2024Expert Review of Hematology

Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons

View Full Paper
Ask AI
Bookmark
Share

Authors

IGInés Gómez‐SeguíInstituto de Salud Carlos IIIMMMaría Eva Mingot‐CastellanoInstituto de Biomedicina de SevillaCPCristina PascualHospital General Universitario Gregorio Marañón

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gómez‐Seguí et al. (2024) studied this question.

synapsesocial.com/papers/68e792cdb6db643587703f92https://doi.org/10.1080/17474086.2024.2318347
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity2022 · 11 citations
  2. 2Delayed normalisation of ADAMTS13 activity in acute Thrombotic Thrombocytopenic Purpura in the caplacizumab era2023 · 31 citations
  3. 3Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura1991 · 1,940 citations
  4. 4Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience2010 · 433 citations
  5. 5Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura2022 · 16 citations